We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




DNA Blood Test Evaluated for Colorectal Cancer Detection

By LabMedica International staff writers
Posted on 11 Jun 2014
Tumor-derived aberrant DNA can be detectable in blood and blood tests have the potential to improve screening for colorectal cancer.

A new blood test for bowel cancer based on two genes that are frequently hyper-methylated in colorectal adenoma and cancer (CRC) tissues, has been assessed for accuracy.

Scientists at Flinders University (Adelaide, SA, Australia) working with their Dutch colleagues enrolled 2,187 volunteers with a mean age of 62 years, 52% of which were male. More...
The patients were scheduled for colonoscopy for any reason, or for resection of colonic neoplasia, and were included if they provided sufficient plasma. The test was run successfully on 2,139 plasma specimens including 30 sample pairs taken pre- and post-surgical removal of neoplastic lesions.

Circulating cell-free DNA was extracted from plasma samples and bisulphite converted. Levels of recovered DNA and methylated Branched Chain Amino-Acid Transaminase 1, Cytosolic (BCAT1) and IKAROS Family Zinc Finger 1 (IKZF1) DNA were simultaneously determined using multiplexed quantitative polymerase chain reactions (qPCR) (Clinical Genomics; Sydney, NSW, Australia). A plasma sample was defined as positive if amplified target sequence signal above background fluorescence was present in any of three replicates in the BCAT1 or IKZF1 qPCR assay. Sensitivity and specificity for neoplasia were estimated as the primary outcome measures.

The two-gene blood test, BCAT1 and/or IKZF1 positive, successfully identified 85/130 (65.4%) of CRC cases. The successful detection rate increased to 73% for cancers that are Stage II or higher. The 12 BCAT1/IKZF1 methylation-positive CRC subjects with paired pre- and post-surgery plasma showed reduction in methylation signal after surgery, with complete disappearance of signal in 10 subjects. The presence of cancer-derived methylated DNA markers in plasma correlated with depth of tumor invasion and given the high rate of marker disappearance after cancer resection, the panel might also be useful to monitor tumor recurrence.

Graeme P. Young, MD, a professor of Gastroenterology and lead author of the study said, “A blood test is likely to overcome some of the barriers to screening with fecal tests. It might prove to be acceptable to those failing to participate in screening using established methods, which at the moment are primarily based around fecal tests.” The study was published on April 12, 2014, in the journal Gastrointestinal Endoscopy.

Related Links:

Flinders University 
Clinical Genomics



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.